Dr David Cutter
Contact information
David Cutter
FRCR, DPhil
Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)
David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013, he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.
Recent publications
-
Perfect is the enemy of good: Reply to Struikmans et al.
Journal article
Aznar MC. et al, (2025), Radiother Oncol, 202
-
Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
Journal article
Jones DA. et al, (2024), Br J Haematol
-
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper.
Journal article
Barrett A. et al, (2024), Br J Haematol
-
Cardiovascular toxicities of radiotherapy: From practical issues to new perspectives.
Journal article
Aznar MC. et al, (2024), Radiother Oncol
-
Translating Between Radiation Dose and Late Toxicity for Lymphoma Survivors: Implications on Toxicity Counseling and Survivorship
Journal article
Cutter DJ. and Aleman BMP., (2024), Seminars in Radiation Oncology